Emergent BioSolutions is down -11.4%, or -$1.59 to $12.41.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions sees FY23 revenue $1.1B-$1.2B, consensus $1.18B
- Emergent BioSolutions sees Q1 revenue $130M-$150M, consensus $245.9M
- Emergent BioSolutions reports Q4 EPS (31c), consensus 4c
- Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
- Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use